Bile acids (BAs) play important roles not only in lipid metabolism, but also in signal transduction. TGR5, a transmembrane receptor of BAs, is an immunomodulative factor, but its detailed mechanism remains unclear. Here, we aimed to delineate how BAs operate in immunological responses via the TGR5 pathway in human mononuclear cell lineages. We examined TGR5 expression in human peripheral blood monocytes, several types of in vitro differentiated macrophages (M/s) and dendritic cells. M/s differentiated with macrophage colony-stimulating factor and interferon-c (Mc-M/s), which are similar to the human intestinal lamina propria CD14 + M/s that contribute to Crohn's disease (CD) pathogenesis by production of pro-inflammatory cytokines, highly expressed TGR5 compared with any other type of differentiated M/ and dendritic cells.
Introduction
The immune system is intricately constituted to maintain homeostasis and avoid excessive or deficient responses against foreign antigens, which causes immunological disorders. Recently, macrophages (M/s), major components of innate immunity, were circumstantially analysed for their characteristics. The study showed that M/s have several subpopulations 1, 2 that were classified broadly into two categories: an inflammatory phenotype that is stimulated to produce pro-inflammatory cytokines such as tumour necrosis factor-a (TNF-a) or an anti-inflammatory phenotype that induces immune tolerance by producing interleukin-10 (IL-10).
Macrophages have been also classified according to their anatomical locations. Intestinal M/s play a role in the maintenance of immunological homeostasis by regulation of some inflammatory cytokines against foreign antigens such as commensal bacteria, even if phagocytic and bactericidal activity remains. 2, 3 We previously reported that mouse intestinal M/s produce IL-10 in response to bacterial stimulation, which prevents an excess immune response. 4 Furthermore, we identified that there are two subsets of resident mouse intestinal M/s, and monocyte chemoattractant protein-1 is important for the composition of IL-10-producing intestinal M/s. 5 Denning et al. 6 also reported that intestinal M/s can induce regulatory T cells.
Inflammatory bowel disease (IBD), including Crohn's disease (CD) and ulcerative colitis, is caused by inadequate immunological responses against luminal antigens, which results in chronic inflammation in some intestinal regions. 7 In IBD, the homeostatic function of intestinal M/s is disrupted and abnormal immune responses of intestinal M/s contribute to the development of chronic inflammation. In fact, it has been reported that M/s expressing the innate-immune receptor CD14 infiltrate the intestinal mucosa of patients with IBD. [8] [9] [10] TREM-1 + M/s in the lamina propria (LP) of patients with IBD mediate chronic inflammation. 11 We also demonstrated that intestinal CD68 + M/s in patients with CD produce most of the IL-18 that contributes to the promotion of the T helper type 1 immune response. 12 Recently, we have identified unique CD33 + CD14 + CD68 + intestinal M/s that strongly contribute to CD pathogenesis by their proinflammatory cytokine production and antigen presentation function that cooperates with T cells and mucosal natural killer cells. 10, 13, 14 Therefore, conditioning of innate immune cells to an immunoregulatory phenotype may become a novel therapeutic strategy. We previously reported that bile acids (BAs) and synthetic retinoic acid receptor agonists can induce IL-12-hypoproducing dendritic cells (DCs). 15, 16 Bile acids play important roles not only in lipid metabolism, but also in signal transduction via several receptors. TGR5, a G-protein coupled receptor, was identified by an exhaustive search of the GenBank DNA database. 17, 18 TGR5 gene expression covers a broad area to varying degrees, [17] [18] [19] including the hepatobiliary system such as liver sinusoidal endothelial cells, 20 gallbladder epithelial cells 21 and elsewhere. TGR5 is considered to be closely associated with various biological functions. In metabolism, BAs promote energy expenditure in brown adipose tissue via activated thyroid hormone, 22 and they increase intestinal glucagon-like peptide-1 secretion for glucose homeostatic control. 23 In the immune system, BAs are classically known to inhibit inflammatory cytokine production. 24, 25 In terms of the immunological function of TGR5, it has recently become evident that CD14 + monocytes show high TGR5 expression 16, 17 and TGR5 expresses on some M/s, such as Kupffer cells. 26 A TGR5 agonist inhibits an atherosclerosis reduced by M/ inflammation. 27 These results suggest that TGR5 can regulate innate immunity.
There are only a few reports detailing the relationships between TGR5 and gut immunity. In an experimental mouse colitis model, TGR5 regulates intestinal inflammation by a reduction in inflammatory cytokines. 28 However, there is no report of a survey of human intestinal samples in terms of gut immunological regulation by TGR5. Recently, we have found that M/s differentiated by macrophage colony-stimulating factor (M-CSF) and interferon-c (IFN-c) (Mc-M/s) show a similar phenotype to that of intestinal CD14 + M/s, which evoke inflammation in patients with IBD, in terms of cytokine production including TNF-a, IL-6 and IL-23, and the expression pattern of cell surface markers. 10 We hypothesized that Mc-M/s mimic LP CD14 + M/s expressing TGR5, and TGR5 signalling can suppress the production of pro-inflammatory cytokines by inflammatory M/s. In the present study, we investigated TGR5 expression in several innate immune cell populations, including Mc-M/s differentiated in vitro and the intestinal CD14 + M/s of patients with CD, and whether a TGR5 agonist can suppress proinflammatory cytokine production by these cells.
Materials and methods

Heat-treated bacterial antigen
Gram-positive Enterococcus faecalis (ATCC29212) was cultured in brain-heart infusion medium. Bacteria were harvested and washed twice with ice-cold PBS (Wako Chemicals, Osaka, Japan). Bacterial suspensions were heated at 80°for 30 min, washed, resuspended in PBS and stored at À 80°. Complete killing was confirmed by 24 hr incubation at 37°on solid growth medium.
In vitro monocyte differentiation
Peripheral blood mononuclear cells were isolated from heparinized peripheral blood samples by density gradient centrifugation using Lymphoprep (Nycomed Pharma, Oslo, Norway). Cells were aspirated from the gradient interface, washed in PBS, and resuspended at 1 9 10 6 cells/ml in RPMI-1640 medium (Sigma-Aldrich, St Louis, MO) containing 10% heat-inactivated fetal bovine serum (BioSource, Camarillo, CA), 100 U/ml penicillin and 100 mg/ml streptomycin (Invitrogen, La Jolla, CA). Monocytes were purified using a magnetic cell separation system (MACS; Miltenyi Biotec, Auburn, AL) with antihuman CD14 microbeads (Miltenyi Biotec). Monocytes were seeded in dishes at a density of 1 9 10 6 cells/2 ml culture medium. Based on a review of monocyte differentiation, 29 some cultures contained 50 ng/ml M-CSF (R&D Systems, Minneapolis, MN) for M-CSF-differentiated macrophages (M-M/s), 50 ng/ml M-CSF and 100 ng/ml IFN-c (R&D) for Mc-M/s, 50 ng/ml granulocyte-macrophage colony-stimulating factor (GM-CSF) (R&D) for GM-CSF-differentiated macrophages (GM-M/ s) or 20 ng/ml GM-CSF and 20 ng/ml IL-4 (R&D) for DCs. After 1, 3 and 6 days, cells were collected. We defined stimulated monocytes for 6 days as completely differentiated. Some samples were used for real-time quantitative PCR (RT-qPCR), immunofluorescence and Western blot analyses.
Peripheral blood samples were collected from healthy donors after obtaining written informed consent. All experiments were approved by the Institutional Review Board of the Keio University School of Medicine.
RT-qPCR analyses
Total RNA was isolated from monocytes using an RNeasy Micro Kit (Qiagen, Washington DC) and reverse transcribed using a Primescript RT Reagent Kit (Takara Bio Inc., Otsu, Japan) according to the manufacturer's instructions. RT-qPCR was performed using a TaqMan Universal PCR Master Mix (Applied Biosystems, Foster City, CA) with gene-specific primers for TGR5 (Hs01937849_s1) and b-actin (Hs99999903_m1) as an internal control. The PCR amplifications were performed using a DNA Engine Opticon 2 system or CFX96 RealTime System (Bio-Rad, Hercules, CA), and data were analysed with OPTICON MONITOR software (MJ Research, Waltham, MA).
TGR5 immunofluorescence
Cells were fixed with 4% paraformaldehyde and blocked in Protein Block serum-free Ready-To-Use (Dako, Glostup, Denmark) for 1 hr at room temperature. Then, cells were incubated with a rabbit anti-TGR5 antibody (Abcam, Cambridge, MA) for 2 hr, followed by an Alexa Fluor 568-conjugated goat anti-rabbit IgG (Molecular Probes, Eugene, OR) for 1 hr, while protected from light. Nuclei were counterstained with Hoechst 33342 trihydrochloride, trihydrate (Invitrogen). The fluorescence images obtained were analysed by LUMINA VISION software (Mitani, Tokyo, Japan).
Stimuli for differentiated monocytes
Differentiated monocytes described above were seeded in 96-well culture dishes at a density of 2 9 10 5 cells/200 ll culture medium. Then, cells were stimulated with the following: heat-killed E. faecalis (multiplicity of infection = 100), lipopolysaccharide (LPS; Sigma), BAs; chenodeoxycholic acid (CDCA; Sigma), deoxycholic acid (DCA; Sigma), lithocholic acid (LCA; Sigma), cholic acid (CA; Nacalai Tesque, Kyoto, Japan) or ursodeoxycholic acid (UDCA; Tokyo Chemical Industry, Tokyo, Japan), a 3-(2-chlorophenyl)-N-(4-chlorophenyl)-N,5-dimethylisoxazole-4-carboxamide as a TGR5 agonist (Bio Vision, Mountain View, CA) which was derived by Evans et al.
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( Fig. 1) , a p38 mitogen-activated protein kinase inhibitor (Merck Millipore, Tokyo, Japan), a toll-like receptor 4 inhibitor (Imgenex, San Diego, CA) or 8-bromoadenosine 3′, 5′-cyclic monophosphate as a cAMP reagent (Sigma). After 1 day of stimulation, supernatants were collected for cytokine assays, and the remaining cells were used for viability assays.
Flow cytometry
For labelling cell surface markers, monoclonal antibodies against CD14, CD33, CD205, CD206, CD209, CD80, CD86, CD1a, CD40, PD-L1, PD-L2, CD16, CD32 and CD64 were purchased from BD Pharmingen (San Jose, CA). Monoclonal antibody against TGR5 was purchased from R&D. The fluorescence intensity of labelled cell surface markers was assessed using an FACS Calibur flow cytometer (BD), and the data were analysed using CELL-QUEST (BD) or FLOWJO (TreeStar Inc., Ashland, OR) software. Dead cells were excluded from analyses by propidium iodide staining. Figure 1 . Chemical structure of the 3-(2-chlorophenyl)-N-(4-chlorophenyl)-N, 5-dimethylisoxazole-4-carboxamide as the TGR5 agonist we used in this study. This compound precursor was discovered by a high-throughput screening of the GlaxoSmithKline Pharmaceuticals (Collegeville, PA) compound library using a luciferase assay, the production of which was caused by cAMP. In the process of exploring substitution derivative analysis, this TGR5 agonist was found out as a high affinity for TGR5 (pEC 50 = 6Á8) of U2-OS cells.
Analysis of cytokine production
Production levels of TNF-a were assessed using a Human Inflammation Cytometric Bead Array Kit (BD) with the FACS Calibur, according to the manufacturer's instructions.
cAMP production assay
Mc-M/s (1 9 10 5 cells) were treated with the TGR5 agonist (10 lM) for 5 min in the presence of 1 mM 3-isobutyl-1-methylxanthine (Sigma). The amount of cAMP was determined with a cAMP-Screen System (Applied Biosystems).
Western blotting
Mc-M/s stimulated by 10 ng/ml LPS and 10 lM TGR5 agonist were used for intracellular signalling protein detection. Cells (1 9 10 5 cells/well of a 96-well plate) were washed with ice-cold PBS containing 0Á1% protease inhibitor cocktail (Sigma), and then lysed in 15 ll RIPA buffer (Thermo Fisher Scientific, Waltham, MA) containing 0Á5% protease inhibitor cocktail (Sigma) and 1 mM Na 3 VO 4 . After centrifugation, supernatants mixed with lithium dodecyl sulphate sample buffer and reducing agents (Invitrogen) were electrophoresed on a Mini PRO-TEAN TGX gel (Bio-Rad). Separated proteins were transferred by an iBlot Dry Blotting System (Invitrogen) according to the manufacturer's instructions. The membrane was immersed in Starting Block T20 (TBS) Blocking Buffer (Thermo Fisher Scientific) for 1 hr. After blocking, primary antibodies were added to the membranes, followed by incubation at 4°overnight. After incubation with a horseradish peroxidase-conjugated antirabbit secondary antibody (Cell Signaling, Danvers, MA), blots were visualized using an Amersham ECL Prime western Blotting Detection Reagent (GE Healthcare, Buckinghamshire, UK) and analysed using an ImageQuant LAS 4000 mini (GE Healthcare). The antibodies used were anti-phospho-c-Fos, anti-c-Fos and anti-b-actin (all Cell Signaling). Immunoblotted membranes were repeatedly used after treatment with a Ten-min Western Blot ReProbe Kit (Jacksun Easy Biotech, Bronx, NY).
Tissue samples
Normal intestinal mucosa was obtained from macroscopically and microscopically unaffected areas in patients with colon cancer as non-IBD samples. Intestinal IBD mucosa was obtained from surgically resected specimens taken from patients with CD and diagnosed based on clinical, radiographic, endoscopic and histological findings, according to established criteria. All experiments were approved by the Institutional Review Board of Keio University School of Medicine and Yokohama Municipal Citizen's Hospital, Inagi Municipal Hospital, and written informed consent was obtained from all patients.
Analysis of lamina propria mononuclear cells
Lamina propria mononuclear cells (LPMCs) were isolated from intestinal specimens using a technique described elsewhere, 31 with some modification. Briefly, dissected mucosa was incubated in calcium and magnesium-free Hanks' balanced salt solution (HBSS) (Sigma) containing 2Á5% heat-inactivated fetal bovine serum and 1 mM dithiothreitol (Sigma) to remove mucus. The mucosa was then incubated twice in HBSS containing 1 mM EDTA (Sigma) for 45 min at 37°. Tissues were collected and incubated in HBSS containing 1 mg/ml collagenase type 3 and 0Á1 mg/ml DNase I (Worthington Biochemical, Lakewood, CO) for 60 min at 37°. Cells were pelleted and resuspended in a 40% Percoll solution (GE Healthcare), and then layered onto 60% Percoll before centrifugation for 20 min at room temperature. Viable LPMCs were recovered from the 40-60% layer interface. CD14 + , CD3 + , CD56 + and CD14
LPMCs were purified using MACS. Cells were used for RT-qPCR analysis of TGR5 and the cytokine production assay.
Cell viability assay
PrestoBlue Cell Viability Reagent (Invitrogen), diluted at 1 : 10 with medium, was added to differentiated monocytes (2 9 10 5 cells/100 ll diluted solution) in a 96-well plate. Samples were then incubated for 30 min at 37°. PrestoBlue is reduced from blue resazurin to red redorufin in the presence of viable cells. Fluorescence (excitation, 570 nm; emission, 600 nm) was measured with a Benchmark plus (Bio-Rad).
Statistical analysis
Statistical analyses were performed using GRAPHPAD PRISM software version 4.0 (GraphPad Software Inc., San Diego, CA). Kruskal-Wallis one-way analysis of variance and the Bonferroni post-hoc test were used for examining statistical differences among more than three groups, and the Student's t-test was used for two groups. A value of P < 0Á05 was considered statistically significant.
Results
Expression of TGR5 in Mc-M/s compared with other peripheral blood monocytes
To investigate the expression of TGR5 among several phenotypes of innate immune cells, we first used RT-qPCR to analyse the TGR5 mRNA level in several types of mononuclear cell lineages differentiated from peripheral blood. The results showed that TGR5 mRNA was down-regulated in almost all M/s and DCs differentiated in vitro, except for Mc-M/s. On day 1, Mc-M/s maintained their TGR5 mRNA level at the same level as that of peripheral CD14 + monocytes (Fig. 2a) . We confirmed that maintenance of the TGR5 mRNA level occurred in an IFN-c concentration-dependent manner (Fig. 2b) . The TGR5 mRNA level of Mc-M/s was conserved on day 6 (Fig. 2c) . In addition, when IFN-c was added to differentiated M-M/s on day 6, IFN-c did not affect the TGR5 mRNA level (Fig. 2d) . These findings suggest that IFN-c stimulation at the initial phase of differentiation is important to maintain the TGR5 mRNA level in M/s. We also analysed TGR5 expression by immunofluorescence and flow cytometry. Mc-M/s expressed more TGR5 proteins than M-M/s (Fig. 2e,f) . The morphology and expression of cell surface markers in Mc-M/s and M-M/s were shown in the Supplementary material, Fig. S1 .
A TGR5 agonist suppresses bacterially induced reduction of TNF-a in Mc-M/s
To demonstrate the anti-inflammatory function of TGR5 signalling in Mc-M/s, we analysed the inhibitory effect of a TGR5 agonist on TNF-a production in Mc-M/s stimulated with commensal bacterial antigen. As expected, the TGR5 agonist significantly suppressed TNF-a production in a concentration-dependent manner (Fig. 3a) . This function was not affected by DMSO (see Supplementary material, Fig. S2 ). The TGR5 agonist did not act in other types of M/s and DCs, which did not express TGR5 (see Supplementary material, Fig. S3a-c) . To confirm that this suppressive function caused an effect on TNF-a produced via the toll-like receptor 4 pathway correctly, we used LPS instead of E. faecalis for stimulation of Mc-M/s. We also found that the TGR5 agonist suppressed LPSinduced TNF-a production (Fig. 3b) , but it did not affect anti-inflammatory cytokine, IL-10 production (see Supplementary material, Fig. S4 ). This TGR5 agonist did not change the cell surface marker on the Mc-M/s (see Supplementary material, Fig. S5 ). With regard to peripheral CD14 + monocytes, which express TGR5, the TGR5 agonist suppressed TNF-a production as well (see Supplementary material, Fig. S6 ). Furthermore, we analysed whether BAs could suppress TNF-a production in the same manner as that of the TGR5 agonist. As shown in Fig. 3(c) , DCA and LCA, which are considered natural TGR5 ligands, suppressed TNF-a production. The viability of Mc-M/s treated with the TGR5 agonist and BAs was not significantly altered (Fig. 3d,e) . To compare with a TGR5 agonist, we used a toll-like receptor 4 inhibitor and a p38 mitogen-activated protein kinase inhibitor for the evaluation of TNF-a inhibition. The inhibitory effect of TGR5 agonist was comparable with that of p38 mitogen-activated protein kinase inhibitor on TNF-a production at 10 mM concentration (Fig. 3f) . It suggests that a TGR5 agonist has an anti-inflammatory effect that compares favourably with other types of anti-inflammatory reagents.
cAMP, a second messenger of TGR5, also suppresses TNF-a production in Mc-M/s
We next investigated whether cAMP, a downstream molecule of TGR5, could suppress TNF-a production in Mc-M/s. As shown in Fig. 4(a, b) , cAMP also suppressed TNF-a production in a similar way to the suppression by the TGR5 agonist in Mc-M/s stimulated with E. faecalis or LPS. The viability of Mc-M/s modified by cAMP was not significantly altered (Fig. 4c) . Consistent with previous reports, [16] [17] [18] 23, 27, 28 the TGR5 agonist also up-regulated cAMP in Mc-M/s (Fig. 4d) and induced phosphorylation of c-Fos (Fig. 4e) after LPS stimulation.
Intestinal CD14 + M/s from CD patients express TGR5
We previously reported that intestinal CD14 + M/s contribute to the pathogenesis of CD by the production of a large amount of pro-inflammatory cytokines in response to bacterial stimulation. 10 We investigated whether TGR5 expression in the intestinal CD14 + M/s of CD patients was the same as that in in vitro Mc-M/s that mimic CD14 + M/s. The TGR5 mRNA level in LPMCs obtained from inflamed CD mucosa, which was distinguished by TNF-a production (see Supplementary material, Fig. S7 ), exhibited significantly up-regulated TGR5 mRNA, compared with that in the LPMCs of patients without IBD (Fig. 5a) . Moreover, isolated CD14 + M/s highly expressed TGR5 mRNA, compared with CD14 + M/-depleted LPMCs (Fig. 5b) . These findings revealed that intestinal CD14 + M/s are the cells that express TGR5 among LPMCs. Importantly, the TGR5 agonist suppressed bacterially stimulated TNF-a production in CD LPMCs (Fig. 6a) and isolated CD14 + M/s (Fig. 6b) .
Discussion
In this study, we demonstrated that TGR5, which is a Gprotein coupled receptor for BAs, is expressed in both the Mc-M/s and intestinal CD14 + M/s of patients with CD, which produce large amounts of TNF-a in response to bacterial stimuli, and that a TGR5 agonist can suppress such a response. It has been reported that TGR5 is expressed in human peripheral monocytes. 16, 17 Although transcriptional regulation of TGR5 has not been identi- Recently, it has been suggested that TGR5 plays a role in immunological regulation via cAMP, a second messenger with an immunoregulatory function. 16, 17, 27, 28 Based on the inhibiting effect of inhibitor of nuclear factor-jBa (IjBa), Wang et al. 32 reported an inhibitory mechanism of NF-jB, in which TGR5 enhances the cytosolic protein b-arrestin 2 that inhibits phosphorylation of IjBa by bacterial antigen stimulation, resulting in suppression of TNF-a production. Pols et al. 27 also reported that TGR5 induces a decrease of phospho-IjBa (p-IjBa). Based on these results, we also examined whether TGR5 inhibits phosphorylation of IjBa, but the TGR5 agonist did not affect the level of p-IjBa in Mc-M/s (data not shown). In other studies, Koga et al. 33 demonstrated that cAMP induced by prostaglandin E 2 suppresses TNF-a transcription by up-regulation of c-Fos that binds to nuclear factor-jB p65 protein, and this complex cannot bind to the TNF promoter in DCs or RAW264.7 cells. In addition, c-Fos is stabilized by phosphorylation from Ij kinase b via the toll-like receptor 4 pathway that is triggered by innate immune responses against bacterial antigen. 33 This inhibition of the TNF-a promoter binding effect is not associated with IjBa. We hypothesized that in mononuclear cell lineages, TGR5 has an immunoregulatory function by inducing cAMP, which is similar to the mechanism of prostaglandin E 2 . In our experiments, the concentration of cAMP in Mc-M/s was increased by Results are shown as the means AE SEM from three independent experiments as relative percentages of TNF-a levels in CD14 + intestinal M/s stimulated with E. faecalis only. Statistical analysis was performed by Kruskal-Wallis one way analysis of variance and the Bonferroni post-hoc test for multiple comparisons. **P < 0Á01.
treatment with the TGR5 agonist that induced phosphorylation of c-Fos (p-c-Fos). These findings suggest that the TGR5 agonist may suppress TNF-a transcription via p-cFos in Mc-M/s. Several BAs, including both primary and secondary BAs, have been reported as natural ligands of TGR5. Of these BAs, LCA activates TGR5 with an EC 50 of 600 nM, suggesting that LCA is a physiological ligand for TGR5, whereas UDCA has low affinity. 17, 24, 34 Consistent with previous observations, our study indicated that DCA and LCA had an anti-inflammatory potential (Fig. 3c) . In our study, the TGR5 agonist and BAs did not affect the viability of M/s (Fig. 3d,e) . Although the detailed mechanism is not clarified on the Mc-M/s, Sato et al. 35 investigated the binding affinity of BAs to TGR5 from the aspect of chemical structures by luciferase assay methods on TGR5-transfected Chinese hamster ovary (CHO) cells. They revealed that TGR5 were highly bound to LCA, DCA, CDCA, CA and UDCA in this order. Their binding affinity to TGR5 was affected by the absence or existence of hydroxylation in positions 6, 7 and 12 of the steroid ring, which was constituted of bile acids. LCA and DCA do not have a hydroxylation at 7 of the steroid ring, but others have one. It is possible that the binding affinity to TGR5 on the Mc-M/s depends on the molecular structure of BAs. Both DCA and LCA have fewer hydroxyl groups, suggesting that a hydrophobic structure facilitates binding to TGR5.
Importantly, the TGR5 agonist suppressed TNF-a production by intestinal CD14 + M/s that play a central role in the pathogenesis of CD. Modification and conditioning of innate immune cells have been considered as therapeutic strategies for treating chronic inflammatory disorders such as CD. Previously, we reported that tetomilast (OPC-6535), which inhibits phosphodiesterase-4, suppresses production of pro-inflammatory cytokines in human M/s. 36 Retinoic acid receptors and TGR5 affect the differentiation process of DCs and induce an IL-12-hypoproducing DC phenotype. 15, 16 Here, we demonstrated that a TGR5 agonist suppressed TNF-a production by the inflammatory phenotype of M/s. Although a precise mechanism remains unclear, Cipriani et al. 28 reported that TGR5 is associated with regulation of experimental colitis in a mouse model by not only inflammatory cytokine suppression in immune cells, but also by maintaining the epithelial architecture as shown by an abnormal distribution of the epithelial tight junction protein zonulin 1 on the colon in dextran sulphate sodium-induced colitis in TGR5-deficient mice. These results suggest that TGR5 is involved in intestinal homeostasis by regulation of the immune cell response and maintenance of the epithelial barrier function.
In conclusion, our results clearly demonstrate the expression profiles of TGR5 in several mononuclear cell types and the potential of a TGR5 agonist as an antiinflammatory molecule in innate immune cells. Modification of TGR5 signalling may have a potential to regulate immune reaction in chronic inflammatory disorders such as CD.
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